AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22891625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 262
Study 22891625 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Dense
Number of subjects: 262
Study 22891625 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxxion R
Number of subjects: 262
Study 22891625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth survival
Number of subjects: 262
Study 21804338 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter therapy (60 min, twice a week for 2 weeks, total of 4 sessions)
Number of subjects: 67
Study 21804338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laughter therapy)
Number of subjects: 67
Study 19782873 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel surgery
Number of subjects: 116
Study 19782873 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment (including hand therapy and ultrasound)
Number of subjects: 116
Study 16678357 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy from the incisura angularis
Number of subjects: 328
Study 16678357 — intervention group
Group type: COMPARATOR
Intervention: Biopsy from the gastric antrum and corpus
Number of subjects: 328
Study 14964742 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biologic therapies
Number of subjects: 0
Study 10743698 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 3 x 500 mg/day
Number of subjects: 32
Study 10743698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8751104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG-laser iridotomy
Number of subjects: 30
Study 8751104 — intervention group
Group type: COMPARATOR
Intervention: Surgical iridectomy
Number of subjects: 30
Study 2205997 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional intravenous block
Number of subjects: 99
Study 6272442 — intervention group
Group type: EXPERIMENTAL
Intervention: antivitamin K with suloctidil
Number of subjects: 23
Study 6272442 — intervention group
Group type: COMPARATOR
Intervention: antivitamin K alone
Number of subjects: 23
Study 30924165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim at 10 μg/kg/day for at least 4 consecutive days (early collection group)
Number of subjects: 24
Study 30924165 — intervention group
Group type: COMPARATOR
Intervention: Lenograstim at 10 μg/kg/day for at least 4 consecutive days (late collection group)
Number of subjects: 24
Study 28668524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg/h)
Number of subjects: 40
Study 25296654 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA capsule 75 mg/day for at least 12 weeks before egg collection
Number of subjects: 60
Study 25296654 — intervention group
Group type: COMPARATOR
Intervention: Placebo for at least 12 weeks before egg collection
Number of subjects: 60
Study 22725663 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 1000 mg capsules once daily for 14 days
Number of subjects: 18
Study 20102876 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hospital discharge (48-72 hours) with outpatient follow-up by an advanced practice nurse (APN)
Number of subjects: 54
Study 20102876 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge planning and follow-up by treating physician without added nursing intervention
Number of subjects: 54
Study 20102876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 17050564 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 21
Study 17050564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16246997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 2-day safety training program for staff
Number of subjects: 10558
Study 16246997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 2-day safety training program for staff (in facilities with best program compliance)
Number of subjects: 10558
Study 11858336 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse calculation incorporating the position of the center of pressure
Number of subjects: 32
Study 11858336 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of estimating the impulse distribution beneath the foot
Number of subjects: 32
Study 11858336 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with plantar fasciitis
Number of subjects: 32
Study 9952148 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 99
Study 9952148 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 99
Study 9952148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 99
Study 9952148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 99
Study 9952148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 99
Study 9952148 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium and Vecuronium
Number of subjects: 99
Study 9952148 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine and Rocuronium
Number of subjects: 99
Study 7594343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 22
Study 7594343 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg b.i.d.
Number of subjects: 22
Study 2210021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (2 U bolus injection; 111 mU/min for 2 hours)
Number of subjects: 10
Study 2210021 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study 2210021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 10
Study 7471334 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 100
Study 7471334 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management
Number of subjects: 100
Study 7471334 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management (elective nonsurgical group)
Number of subjects: 100
Study 30631161 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 304
Study 30631161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 28740204 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically administered autologous APOSEC (12.5 × 106 PBMCs)
Number of subjects: 10
Study 28740204 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically administered autologous APOSEC (25 × 106 PBMCs)
Number of subjects: 10
Study 28740204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (irradiated medium)
Number of subjects: 10
Study 28740204 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically administered APOSEC (both doses)
Number of subjects: 10
Study 25670636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg on admission, followed by 20 mg/day)
Number of subjects: 220
Study 25670636 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment (control group)
Number of subjects: 220
Study 25670636 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin and No statin treatment (control group)
Number of subjects: 220
Study 24402637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosphere Verigene® System
Number of subjects: 82
Study 24402637 — intervention group
Group type: COMPARATOR
Intervention: Control (reduced metabolisers)
Number of subjects: 82
Study 21334753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg/Simvastatin 20mg (E10/S20)
Number of subjects: 83
Study 21334753 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 80 mg (S80)
Number of subjects: 83
Study 18775622 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid 1 (randomized in 390 women)
Number of subjects: 481
Study 18775622 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid 2 (randomized in 91 mutation carriers)
Number of subjects: 481
Study 18775622 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid 1 and 2
Number of subjects: 481
Study 17519660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitriangular fascia sling (modified Crawford method)
Number of subjects: 19
Study 17519660 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotriangular fascia sling (modified Fox method)
Number of subjects: 19
Study 16749654 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/20 mg
Number of subjects: 247
Study 16749654 — intervention group
Group type: COMPARATOR
Intervention: SIMVA 20 mg
Number of subjects: 247
Study 14996777 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment guidelines tailored for the elderly with care management
Number of subjects: 598
Study 14996777 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 598
Study 10790552 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (MINI)
Number of subjects: 50
Study 10790552 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlaparoscopic cholecystectomy (MICRO)
Number of subjects: 50
Study 10790552 — intervention group
Group type: COMPARATOR
Intervention: Control group (Laparoscopic)
Number of subjects: 50
Study 8988065 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol in extensive metabolizers
Number of subjects: 27
Study 8988065 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol in poor metabolizers
Number of subjects: 27
Study 8988065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 1503482 — intervention group
Group type: EXPERIMENTAL
Intervention: DWA2114R regimen
Number of subjects: 61
Study 1503482 — intervention group
Group type: COMPARATOR
Intervention: CDDP regimen
Number of subjects: 61
Study 6652642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol 80 mg, twice daily for 5 days
Number of subjects: 19
Study 6652642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoprolol 100 mg, twice daily for 5 days
Number of subjects: 19
Study 6652642 — intervention group
Group type: COMPARATOR
Intervention: Placebo after initial treatment
Number of subjects: 19
Study 6652642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol 10 mg
Number of subjects: 19
Study 6652642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol 20 mg
Number of subjects: 19
Study 30902820 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 (120 mg weekly for 12 weeks)
Number of subjects: 67
Study 30902820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 30902820 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064
Number of subjects: 67
Study 29236628 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterBirth program (coaching-based implementation of the WHO Safe Childbirth Checklist)
Number of subjects: 157689
Study 29236628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coaching-based implementation of the WHO Safe Childbirth Checklist)
Number of subjects: 157689
Study 27636757 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy in addition to conventional treatment
Number of subjects: 54
Study 27636757 — intervention group
Group type: EXPERIMENTAL
Intervention: Only photodynamic therapy
Number of subjects: 54
Study 27636757 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 54
Study 24851544 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intensive rehabilitation combined with air (FiO2 = 21%) pressurized to 1.3 atm abs (n = 40)
Number of subjects: 150
Study 24851544 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intensive rehabilitation combined with 100% oxygen pressurized at 1.5 atm abs (n = 32)
Number of subjects: 150
Study 24851544 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intensive rehabilitation combined with 100% oxygen pressurized at 1.75 atm abs (n = 58)
Number of subjects: 150
Study 24851544 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive rehabilitation only (control group n = 20)
Number of subjects: 150
Study 22994867 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoacoustic Advanced Combination Encoder (PACE)
Number of subjects: 20
Study 22994867 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Combination Encoder (ACE)
Number of subjects: 20
Study 22994867 — intervention group
Group type: COMPARATOR
Intervention: Original stimuli
Number of subjects: 20
Study 22994867 — intervention group
Group type: COMPARATOR
Intervention: Simulated stimuli (ACE and PACE)
Number of subjects: 20
Study 19888030 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane sweeping
Number of subjects: 213
Study 19888030 — intervention group
Group type: COMPARATOR
Intervention: Control (weekly vaginal assessment for Bishop score)
Number of subjects: 213
Study 17513664 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg hyperbaric bupivacaine
Number of subjects: 80
Study 17513664 — intervention group
Group type: COMPARATOR
Intervention: 6.0 mg hyperbaric bupivacaine
Number of subjects: 80
Study 15159466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 to 30 mg/day
Number of subjects: 24
Study 15159466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11591616 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagas' heart disease patients (CH) during hypoxia
Number of subjects: 12
Study 11591616 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects (C) during hypoxia
Number of subjects: 12
Study 11591616 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagas' heart disease patients (CH) during hypercapnia
Number of subjects: 12
Study 11591616 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects (C) during hypercapnia
Number of subjects: 12
Study 9542516 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected group (FOB screening)
Number of subjects: 150000
Study 9542516 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders (no screening)
Number of subjects: 150000
Study 9542516 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 150000
Study 8300690 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 80
Study 8300690 — intervention group
Group type: COMPARATOR
Intervention: Debridement
Number of subjects: 80
Study 3182116 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienamycin
Number of subjects: 0
Study 3182116 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 0
Study 30467829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 20
Study 30467829 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma
Number of subjects: 20
Study 27585447 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month guided hiking programme (2-3 times a week)
Number of subjects: 48
Study 27585447 — intervention group
Group type: COMPARATOR
Intervention: Activities of daily living (control group)
Number of subjects: 48
Study 26424091 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes with 1.6% and 2.4% nicotine
Number of subjects: 24
Study 26424091 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 24
Study 26424091 — intervention group
Group type: COMPARATOR
Intervention: Conventional tobacco cigarette
Number of subjects: 24
Study 23382519 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (LF) SPG stimulation for 3 minutes
Number of subjects: 6
Study 23382519 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency (HF) SPG stimulation for treatment
Number of subjects: 6
Study 23382519 — intervention group
Group type: COMPARATOR
Intervention: High frequency (HF) SPG stimulation for 3 minutes
Number of subjects: 6
Study 22142327 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Message Service with Interactive Voice Response (SMS-IVR) intervention, including training of professionals (medical oncologists, nurses, and general practitioners)
Number of subjects: 0
Study 22142327 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard care without SMS-IVR)
Number of subjects: 0
Study 19159726 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 36
Study 19159726 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 36
Study 19159726 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS
Number of subjects: 36
Study 17573989 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine gastrointestinal therapeutic system
Number of subjects: 7665
Study 15118469 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic cyclophotocoagulation (ECP)
Number of subjects: 68
Study 15118469 — intervention group
Group type: COMPARATOR
Intervention: Ahmed drainage implant
Number of subjects: 68
Study 12419034 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 72
Study 10030556 — intervention group
Group type: EXPERIMENTAL
Intervention: N2/CO2 gas mixture exposure for 1 hour
Number of subjects: 35
Study 7553416 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Number of subjects: 77
Study 7553416 — intervention group
Group type: COMPARATOR
Intervention: clindamycin plus gentamicin
Number of subjects: 77
Study 1979522 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) 50 mg/kg once a week in a 3-hour infusion with 1 g oral probenecid
Number of subjects: 30
Study 1979522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6106322 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 20
Study 6106322 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 20
Study 6106322 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin and Cimetidine
Number of subjects: 20
Study 31797844 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen dressing
Number of subjects: 45
Study 31797844 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cure dressing
Number of subjects: 45
Study 31797844 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-eugenol-based dressing
Number of subjects: 45
Study 31797844 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 45
Study 27835050 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of Chromium Picolinate (600 mcg/day)
Number of subjects: 24
Study 27835050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27835050 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin AUC (all groups)
Number of subjects: 24
Study 27835050 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Sensitivity Index (ISI) (all groups)
Number of subjects: 24
Study 25549827 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing and disinfection of toys and linen every two weeks for three months
Number of subjects: 587
Study 25549827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 587
Study 23864641 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2 inhalation during LBNP
Number of subjects: 11
Study 23864641 — intervention group
Group type: COMPARATOR
Intervention: SHAM (room air) during LBNP
Number of subjects: 11
Study 21118266 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of intra-operative autologous whole blood
Number of subjects: 20
Study 19179490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (100,000 IU of cholecalciferol)
Number of subjects: 365
Study 19179490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 19179490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 365
Study 17298973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 0
Study 17298973 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 15945548 — intervention group
Group type: EXPERIMENTAL
Intervention: spiramycin + lidase
Number of subjects: 19
Study 15945548 — intervention group
Group type: EXPERIMENTAL
Intervention: lincomycin + lidase
Number of subjects: 19
Study 15945548 — intervention group
Group type: COMPARATOR
Intervention: co‐trimoxazole, metronidazole
Number of subjects: 19
Study 11149999 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (200 microg per nostril)
Number of subjects: 11
Study 11149999 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 11
Study 9305478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (group A)
Number of subjects: 72
Study 9305478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 250 mg q.d.s (group B)
Number of subjects: 72
Study 8103372 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg)
Number of subjects: 26
Study 8103372 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.015 micrograms.kg/min)
Number of subjects: 26
Study 3095522 — intervention group
Group type: EXPERIMENTAL
Intervention: High aluminum load from experimental high calcium- and phosphorus-containing PN solution (306 +/- 26 micrograms/L) for up to 6 weeks
Number of subjects: 20
Study 3095522 — intervention group
Group type: COMPARATOR
Intervention: Lower aluminum load from standard Ca-P solutions (144 +/- 16 micrograms/L)
Number of subjects: 20
Study 3095522 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 20
Study 29517580 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (topical prostaglandins)
Number of subjects: 904
Study 29517580 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (topical beta blockers and carbonic anhydrase inhibitors)
Number of subjects: 904
Study 29517580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraocular pressure-lowering medications)
Number of subjects: 904
Study 28288051 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 240
Study 28288051 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study 26153365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-thalidomide-dexamethasone (VTD)
Number of subjects: 98
Study 26153365 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) negative patients
Number of subjects: 98